Heavy Metal Testing & DMSA Chelation — Environmental Medicine & Toxin Avoidance
Medical assessment and treatment of heavy metal accumulation (lead, mercury, arsenic, cadmium) using FDA-approved chelating agents under physician supervision.
Overview
Heavy metal accumulation — particularly lead (cognitive impairment, cardiovascular risk, renal disease), mercury (neurological effects, thyroid disruption), arsenic (carcinogenesis, diabetes risk), and cadmium (renal toxicity, bone demineralization) — represents a significant and underdiagnosed environmental health burden. The TACT trial (Trial to Assess Chelation Therapy, JAMA 2013, n=1,708) found EDTA chelation in post-MI patients with diabetes reduced secondary cardiovascular events by 41% — a striking result that remains controversial and under replication. DMSA (2,3-dimercaptosuccinic acid, trade name Chemet) is FDA-approved for lead poisoning in children with BLL > 45 μg/dL and is used off-label for mercury, arsenic, and lead in adults. Andy Cutler's low-dose frequent DMSA/DMPS/ALA chelation protocol is popular in the integrative community for low-level metal burden. Mercury sources include dental amalgam fillings, large predatory fish (tuna, swordfish, shark), and occupational exposure. Lead sources include old paint (pre-1978), imported ceramics, and some herbal supplements.
Indications
- Documented heavy metal elevation (blood lead, mercury, arsenic, cadmium on validated testing)
- Occupational heavy metal exposure (welding, battery manufacturing, mining)
- Unexplained cognitive decline, neuropathy, or renal dysfunction with environmental risk
- Post-amalgam removal mercury exposure management
- Cardiovascular risk reduction in patients with elevated lead burden
Mechanism of Action
DMSA contains two thiol groups (sulfhydryl -SH) that form stable five-membered ring complexes with heavy metal ions — these DMSA-metal complexes are water-soluble and excreted renally
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| DMSA (Chemet) — physician prescribed | 10 mg/kg per dose, three times daily | 5 days on, 9 days off (one 'round'); repeat 3-24+ rounds | FDA-approved for pediatric lead poisoning; used off-label in adults; available compounded |
| Alpha-Lipoic Acid (ALA) — Cutler Protocol | 25-50 mg per dose | Every 3 hours around the clock, concurrent with DMSA rounds | ALA crosses blood-brain barrier; strict every-3-hour timing required due to short half-life; used in Cutler ACC protocol for mercury detox |
Evidence Grade
GRADE B
Safety & Contraindications
- Never self-chelate without physician supervision — mobilizing heavy metals without appropriate binding can redistribute metals to the brain
- DMSA can cause liver enzyme elevation, rash, GI distress, neutropenia — monitor CBC and liver function
- DMSA chelates essential minerals (zinc, copper, magnesium) concurrently — mineral supplementation required during rounds
- IV EDTA for mercury (used by some practitioners) is NOT appropriate — EDTA does not effectively chelate mercury; can worsen distribution
- Provoked urine testing (challenging with chelation agent then measuring urine metals) is controversial — may overestimate body burden; not recommended by mainstream toxicology
- Andy Cutler Protocol requires strict q3-4 hour ALA dosing — missing doses can cause 'redistribution' symptoms